Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 7, 2014, Pages 1247-1252

  Bourgeois, N ^a   Laurens, C ^a   Bertout, S ^b   Balard, Y ^a   Krasteva, D ^b   Rispail, P ^a   Lachaud, L ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FKS1 PROTEIN; FKS2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ECHINOCANDIN; FUNGAL PROTEIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA GLABRATA; CONTROLLED STUDY; EPSILOMETER TEST; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; GENE MUTATION; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES;

CANDIDA GLABRATA; ECHINOCANDINS; FUNGAL PROTEINS; GENOTYPING TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84903815566     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2069-z     Document Type: Article

References (17)

1. Arendrup MC, Pfaller MA; Danish Fungaemia Study Group (2012) Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother 56(7):3965-3968
2. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M (2011) Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 38(1):65-69
3. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1): 133-163 (Pubitemid 46167771)
4. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503-535
5. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD et al (2013) Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 19(8):E343-E353
6. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al ESCMID Fungal Infection Study Group (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19-37
7. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F et al (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55(2):532-538
8. Cota JM, Grabinski JL, Talbert RL, Burgess DS, Rogers PD, Edlind TD et al (2008) Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother 52(3): 1144-1146 (Pubitemid 351358401)
9. Beyda ND, Lewis RE, Garey KW(2012) Echinocandin resistance in Candida species:mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 46(7-8):1086-1096
10. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T et al (2010) FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 54(12):5042-5047
11. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M et al (2010) Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 54(5):2225-2227
12. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732
13. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2008) EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14(4):398-405
14. Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Jiménez Díez-Canseco L, Gómez- Garcés JL et al (2012) Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob Agents Chemother 56(6):3417-3419
15. EM Consulte (2004) Prise en charge des candidoses et aspergilloses invasives de l'adulte. Available online at: http://www.em-consulte.com/article/ 93871/alertePM
16. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E et al (2013) Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57(12):5836-5842
17. Arendrup MC, Rodriguez-Tudela J-L, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M et al (2011) Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 55(4):1580-1587